Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
NCTID
NCT02599922
(View at clinicaltrials.gov)
Description
This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-401 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.
(Show More)
Development Status
Inactive
Indication
Achromatopsia
Disease Ontology Term
DOID:0110008
Compound Name
AGTC-401
Compound Description
rAAV2tYF-PR1.7-hCNGB3
Sponsor
Beacon Therapeutics
Funder Type
Industry
Recruitment Status
Active not recruiting
Enrollment Count
32
Results Posted
Not Available
Therapy Information
Target Gene/Variant
CNGB3
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Functional gene replacement
Route of Administration
Subretinal
Drug Product Type
Viral vector
Target Tissue/Cell
Cone cells
Delivery System
Viral transduction
Vector Type
AAV2tYF
Editor Type
none
Dose 1
2E11 vg/ml
Dose 2
4E10 vg/ml
Dose 3
1.2E11 vg/ml
Dose 4
3.6E11 vg/ml
Dose 5
1.1E12 vg/ml; Dose 6: 3.2E12
Study Record Dates
Current Stage
Phase1, Phase2
Submit Date
2015-11-05
Completion Date
2026-07
Last Update
2022-07-22
Participation Criteria
Eligible Age
>=4 Years
Standard Ages
Child, Adult, Older adult
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
8
Locations
United States
Regulatory Information
Has US IND
True
FDA Designations
Recent Updates
Development discontinued by Sponsor
Resources/Links
News and Press Releases
Beacon Clinical Trials and Pipeline
SEC Form 10-K: AGTC Annual Report for FY 2022
Preclinical Publications
Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia
Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases
Safety and Biodistribution Evaluation in CNGB3-Deficient Mice of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia
Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia
Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3-Mutant Dogs